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Why Microbicides for
Women?

W

omen are at disproportionate risk for HIV infection—and urgently need new tools they can use to protect
their own health. Products called microbicides are being developed as vaginal rings, films and tablets

and as rectal and dual-compartment gels that could be used both vaginally and rectally to help prevent sexual
transmission of HIV. These products are based on the same types of antiretroviral (ARV) drugs already being
used successfully to treat and prevent HIV.

Women and Girls Bear the Burden of
the HIV/AIDS Epidemic
n HIV/AIDS is one of the world’s leading causes of
death in women ages 15-49.i Over half of all adults
living with HIV/AIDS are women.ii The epidemic takes
a disproportionate toll in sub-Saharan Africa, where six
of every 10 adults living with HIV/AIDS are women.iii

and girls, along with their families, are more likely to
be malnourished, in poor health and impoverished—
all factors that further increase susceptibility to HIV
infection.

n New HIV infections among women and girls
continue at an alarming rate. Each day, more than
1,800 women and girls acquire HIV.ii In sub-Saharan
Africa, 63% of all new HIV infections are among women and girls, and young women ages 15-24 are three
times as likely to acquire HIV as young men.iii
n Women are particularly susceptible to HIV.
Heterosexual sex remains the primary mode of HIV
transmission in sub-Saharan Africa, and a combination
of biology and gender inequities, including
gender-based violence, renders women more susceptible to HIV infection than men.

In sub-Saharan Africa, young
women ages 15-24 are more than
three times as likely to acquire HIV
as young men of the same age.iii
n Caregiving for those living with HIV/AIDS often
falls to women and girls, limiting their opportunities.vi Many female caregivers have little extra time
to earn money, produce food or attend school while
supporting their families. Consequently, these women

Reducing maternal mortality is difficult in countries hit hard by HIV, a
contributor to death in pregnant women and new mothers.

n HIV/AIDS has a significant impact on the health
of pregnant women and new mothers. Women of
reproductive age are at high risk for HIV infection, and
women may be two to four times as likely to acquire
HIV during pregnancy and the postpartum period.iv
Pregnancy also exacerbates the symptoms and effects
of HIV, and many women living with HIV in developing countries learn that they are infected only after
they become pregnant. Globally, a substantial proportion of deaths among women living with HIV occur
during pregnancy or postpartum,v and a study of three
African sites estimated that women living with HIV
faced a more than fivefold risk of maternal death than
HIV-negative women.vi New woman-centered prevention tools would help reduce maternal mortality.
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New Woman-controlled Prevention
Options are Urgently Needed
A range of prevention choices are needed to control
the epidemic among women. Many women are unable
to negotiate with their partners to use condoms, or to even
plan the timing of sex. In addition, while daily ARV pills
called PrEP (or pre-exposure prophylaxis) are also highly
effective and being made available in many countries, some
women are not able to—or choose not to—use a daily pill or
future methods like an injectable. Controlling the epidemic will require a range of options so a woman can choose
the product that best meets her individual needs and life
circumstances.
Microbicides could offer women discreet methods to
protect their sexual and reproductive health on their
own terms. One microbicide has been found to reduce
women’s HIV risk in large clinical trials: the monthly
dapivirine vaginal ring. The nonprofit International Partnership for Microbicides (IPM) designed the flexible silicone
ring to slowly release the ARV dapivirine. Women insert
the ring themselves and replace it each month. The product
received a positive opinion from the EMA in 2020 and a
recommendation from the WHO in 2021. IPM is seeking
regulatory approvals for the ring’s use in countries in eastern
and southern Africa where HIV incidence among women is
high and they urgently need new prevention choices.
Regulatory approval was received in Zimbabwe and several other countries in the region in 2021, with additional
reviews underway.

Microbicides would complement existing HIV
prevention methods. The dapivirine microbicide ring
would help fill a gap by adding a long-acting method
designed specifically for women to a comprehensive HIV
prevention toolkit that currently includes condoms, daily
oral PrEP, treatment-as-prevention and male circumcision.
Other promising tools in development include ARV-based
injectables and implants, long-acting oral PrEP, rectal and
dual-compartment gels and vaccines.

Modeling studies show that a combination
approach is needed to end the epidemic—
and that microbicides like the dapivirine ring
could have a meaningful impact as part of
that approach.
Realizing the promise of microbicides requires
continued support. Between 2018 and 2019, global investment in overall microbicide research and development fell
6%, from US$163 million to US$154 million.vii Sustained
funding to develop a diverse product pipeline that uses new
mechanisms of actions and different formulations is critical
to meeting the urgency of the epidemic and staying ahead of
the virus. Safe and effective microbicides would help
empower women to protect themselves from HIV/AIDS
and alter the course of the epidemic.

Microbicides that combine an ARV with a contraceptive are also being developed to protect against HIV
and unintended pregnancy, a major contributor to
maternal mortality. Together, HIV and maternal mortality
are two of the leading risks to women’s health worldwide.
Among such multipurpose products in development is
IPM’s three-month ring designed to slowly release dapivirine along with the contraceptive hormone levonorgestrel.
Encouraging results from two safety clinical trials supported the product’s continued development. In addition, IPM
reformulated the ring to increase its firmness due to some
participant reports of slippage and is planning a Phase I trial
of the reformulated ring in 2022.
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